Extended Data Figure 6.

a,HFD decreased acetate, butyrate, and propionate concentration, whereas iso-Valeric acid and Valeric acid increased in stool samples from K-ras^G12Dint mice and littermate controls (ND: LSL-K-ras^G12D/+ controls n=6, K-ras^G12Dint mice n=8; HFD: LSL-K-ras^G12D/+ controls n=7, K-ras^G12Dint mice n=11). P-values were determined by one-way ANOVA and adjusted for the number of comparisons with the Bonferroni method. Error bars indicate s.e.m. *P ≤ 0.05, **P ≤ 0.001, ***P ≤ 0.0001. b, SCFA concentrations of small intestinal (LSL-K-ras^G12D/+ controls n=4, K-ras^G12Dint mice n=4) and colonic samples (LSL-K-ras^G12D/+ controls n=3, K-ras^G12Dint mice n=5) from K-ras^G12Dint and control littermates on HFD supplemented with arabinogalactan. P-values were determined by one-way ANOVA followed by Bonferroni’s multiple comparison test. Error bars indicate s.e.m. *P ≤ 0.05, **P ≤ 0.001, ***P ≤ 0.0001. c, FACS analysis of cells from lamina propria (LP) and mesenteric lymph nodes (MLN) revealed compromised DC recruitment and decreased surface antigen presentation on HFD following supplementation with GOS. (HFD: LSL-K-ras^G12D/+ controls n=2, K-ras^G12Dint mice n=2; HFD+GOS: LSL-K-ras^G12D/+ controls n=5, K-ras^G12Dint mice n=3). P-values were determined by one-way ANOVA and adjusted for the number of comparisons with the Bonferroni method. Error bars indicate s.e.m. The differences were not significant.